Zacks Research Issues Pessimistic Estimate for IRWD Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Stock analysts at Zacks Research reduced their Q2 2025 EPS estimates for Ironwood Pharmaceuticals in a research note issued to investors on Wednesday, May 28th. Zacks Research analyst R. Department now anticipates that the biotechnology company will post earnings of ($0.04) per share for the quarter, down from their prior estimate of $0.03. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.10 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals’ FY2025 earnings at $0.07 EPS, Q2 2026 earnings at $0.06 EPS and FY2027 earnings at ($0.01) EPS.

Other analysts have also issued reports about the company. Wells Fargo & Company restated an “equal weight” rating and issued a $1.00 target price (down from $7.00) on shares of Ironwood Pharmaceuticals in a research note on Tuesday, April 15th. Leerink Partners dropped their target price on shares of Ironwood Pharmaceuticals from $3.00 to $1.00 and set a “market perform” rating for the company in a research note on Monday, April 14th. Jefferies Financial Group reiterated a “hold” rating and set a $0.70 target price (down from $8.00) on shares of Ironwood Pharmaceuticals in a research report on Tuesday, April 15th. Craig Hallum lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 16th. Finally, Citizens Jmp downgraded Ironwood Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Monday, April 14th. Seven equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $4.78.

Ironwood Pharmaceuticals Price Performance

NASDAQ IRWD opened at $0.60 on Monday. The stock’s 50 day simple moving average is $0.89 and its 200 day simple moving average is $2.26. Ironwood Pharmaceuticals has a one year low of $0.53 and a one year high of $7.11. The firm has a market cap of $97.64 million, a PE ratio of -20.11 and a beta of 0.37.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its earnings results on Wednesday, May 7th. The biotechnology company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.09). Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The firm had revenue of $41.14 million during the quarter, compared to analyst estimates of $67.02 million.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of IRWD. Armistice Capital LLC boosted its stake in Ironwood Pharmaceuticals by 44.7% in the first quarter. Armistice Capital LLC now owns 13,700,000 shares of the biotechnology company’s stock valued at $20,139,000 after acquiring an additional 4,232,000 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Ironwood Pharmaceuticals by 5.5% in the 4th quarter. Renaissance Technologies LLC now owns 9,066,241 shares of the biotechnology company’s stock valued at $40,163,000 after purchasing an additional 469,043 shares during the period. Millennium Management LLC boosted its position in shares of Ironwood Pharmaceuticals by 186.6% in the 1st quarter. Millennium Management LLC now owns 6,359,682 shares of the biotechnology company’s stock worth $9,349,000 after purchasing an additional 4,140,439 shares during the last quarter. Jane Street Group LLC grew its stake in shares of Ironwood Pharmaceuticals by 740.5% during the first quarter. Jane Street Group LLC now owns 3,510,117 shares of the biotechnology company’s stock worth $5,160,000 after purchasing an additional 3,092,475 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of Ironwood Pharmaceuticals by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 3,306,570 shares of the biotechnology company’s stock worth $14,652,000 after purchasing an additional 13,028 shares during the period.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.